Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter.

Gupta, Dhiraj; Ding, Wern Yew; Calvert, Peter; Williams, Emmanuel; Das, Moloy; Tovmassian, Lilith; Tayebjee, Muzahir H; Haywood, Guy; Martin, Claire A; Rajappan, Kim; Bates, Matthew G D; Temple, Ian Peter; Reichlin, Tobias; Chen, Zhong; Balasubramaniam, Richard N; Ronayne, Christina; Clarkson, Nichola; Morgan, Maureen; Barton, Janet; Kemp, Ian; ... (2023). Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter. Heart (British Cardiac Society), 109(5), pp. 364-371. BMJ Publishing Group 10.1136/heartjnl-2022-321729

Text heartjnl-2022-321729.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Author holds Copyright Download (1MB)

OBJECTIVE

We aimed to compare cryoballoon pulmonary vein isolation (PVI) with standard radiofrequency cavotricuspid isthmus (CTI) ablation as first-line treatment for typical atrial flutter (AFL).

METHODS

Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter was an international, multicentre, open with blinded assessment trial. Patients with CTI-dependent AFL and no documented atrial fibrillation (AF) were randomised to either cryoballoon PVI alone or radiofrequency CTI ablation. Primary efficacy outcome was time to first recurrence of sustained (>30 s) symptomatic atrial arrhythmia (AF/AFL/atrial tachycardia) at 12 months as assessed by continuous monitoring with an implantable loop recorder. Primary safety outcome was a composite of death, stroke, tamponade requiring drainage, atrio-oesophageal fistula, pacemaker implantation, serious vascular complications or persistent phrenic nerve palsy.

RESULTS

Trial recruitment was halted at 113 of the target 130 patients because of the SARS-CoV-2 pandemic (PVI, n=59; CTI ablation, n=54). Median age was 66 (IQR 61-71) years, with 98 (86.7%) men. At 12 months, the primary outcome occurred in 11 (18.6%) patients in the PVI group and 9 (16.7%) patients in the CTI group. There was no significant difference in the primary efficacy outcome between the groups (HR 1.11, 95% CI 0.46 to 2.67). AFL recurred in six (10.2%) patients in the PVI arm and one (1.9%) patient in the CTI arm (p=0.116). Time to occurrence of AF of ≥2 min was significantly reduced with cryoballoon PVI (HR 0.46, 95% CI 0.25 to 0.85). The composite safety outcome occurred in four patients in the PVI arm and three patients in the CTI arm (p=1.000).

CONCLUSION

Cryoballoon PVI as first-line treatment for AFL is equally effective compared with standard CTI ablation for preventing recurrence of atrial arrhythmia and better at preventing new-onset AF.

TRIAL REGISTRATION NUMBER

NCT03401099.

Interest & Impact

Downloads

2 since deposited on 21 Nov 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item